The future of Belgium's biopharma by Health, Science and Technology group (HST)

Established in 2007, the Health, Science and Technology Group (HST) unites leading biopharma names GSK, Johnson & Johnson, Pfizer and UCB with a shared goal of positioning Belgium as a global leader in biopharma with an ecosystem that’s attractive for investors. Their policy recommendations prioritise stability, research incentives and talent upskilling. Belgium, being the third-largest exporter of medicines in Europe, relies on this industry for significant revenue and job creation. The Group also emphasises collaboration among the sector, academia and the government to nurture scientific and innovation breakthroughs, ensuring the country’s continued excellence in the field of healthcare.

The discussion highlighted key factors contributing to Belgium’s thriving biopharma ecosystem like connectivity, open collaboration, and a focus on innovation. As well it also brought up the challenges that were slowing down the growth of the industry. The discussion compared the progress made by neighbouring countries as well as why and how other global players like the United States are emerging as a force to watch out for.  In order to strengthen and progress the sector’s competitiveness, HST also outlines the necessary measures in this discussion such as finding a harmonious balance between enacting regulation and encouraging innovation.